A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. Fraser DA, Wang X, Lund J, Nikolic N, et al. J Hepatol 2022;76:800-811.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fraser DA, Wang X, Lund J, Nikolic N, et al. A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. J Hepatol 2022;76:800-811.
PMID: 34915054